Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 484 participants.
Also called NCT07632898
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 484 participants
- Sponsor
- Inhibikase Therapeutics
- Registry
-
NCT07632898
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07632898. Allocation not applicable; no masking; primary purpose treatment. Start 2026-10-23 (anticipated); primary completion 2030-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- Condition
- Pulmonary Arterial Hypertension (PAH)
- Intervention (Drug)
- IKT-001
- Lead sponsor
- Inhibikase Therapeutics
Record details
- Record id
cardio:ct-nct07632898- Content hash
e72f6e10eacc0601a89f17503c400bd08eb99b9c6eda08aacc9b482bee62f520